ArticleJournal of diabetes2025
Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019-2022).
Article in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Cardiovascular-kidney-metabolic syndrome stages and increased risk of all-cause and cause-specific mortality in UK Biobank.American journal of preventive cardiology · 2026Article
- Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundCardiovascular-kidney-metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.
methodsThis 3-year longitudinal study (2019-2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low-risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1-2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high-risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC-MS/MS.
resultsHigher AGEs levels showed significant associations with CKM severity, with each 1-SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%-54%). Quartile analysis revealed a dose-response relationship (Q2:1.66[1.15-2.41]; Q3:1.67[1.12-2.48]; Q4:1.92[1.31-2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06-2.45), 1.64 (1.11-2.41), 1.71 (1.07-2.73), and 2.03 (1.32-3.13), respectively.
conclusionsThese findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.